Teva and Active Biotech Announce Discontinuation of Higher Doses of Laquinimod in Two Multiple Sclerosis Trials Active Biotech, 4 Jan 2016 Accessed on 6 Jan 2016 from http://www.activebiotech.com/press-releases-1?pressid=1976427. CommentRecommendBookmarkWatch